Department of Anesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Department of Critical Care, Max Hospital, Mohali, India.
J Ultrasound Med. 2021 Nov;40(11):2451-2457. doi: 10.1002/jum.15632. Epub 2021 Jan 15.
Neurological manifestations, including raised intracranial pressures, are a hallmark of worsening pre-eclampsia. Invasive methods for measuring intracranial pressure, though a gold standard, are not always a viable option. Maternal ocular sonography is a promising bedside tool, which serves as a noninvasive, cost-effective means for measuring optic nerve sheath diameter (ONSD), a surrogate marker of raised intracranial pressures. We studied the ultrasonographically measured ONSD in severely pre-eclamptic women, and the effect of magnesium sulfate therapy on its values.
Thirty severely pre-eclamptic women at ≥28 weeks gestation were included. We recorded baseline ONSD values, serum magnesium levels, neurological symptoms, vitals, and repeated them at 4 and 12 hours following magnesium sulfate therapy, and then at 24 hours postpartum. An ONSD value >5.8 mm was suggestive of raised intracranial pressure. Primary outcome measure was to evaluate changes in ultrasonographically measured ONSD following seizure prophylaxis with magnesium sulfate.
Women, 73.3%, had baseline ONSD >5.8 mm, with mean diameter being significantly high (6.02 ± 0.77 mm). There was a statistically nonsignificant decline in mean ONSD values at 4 and 12 hours, as well as at 24 hours postpartum. Patients with neurological symptoms declined significantly (from 70 to 10%; p value <.001) following magnesium sulfate therapy.
Majority of severely pre-eclamptic parturients had high ONSD value suggestive of raised intracranial pressures, which persisted in the postpartum period and was unaffected by magnesium sulfate therapy. Ultrasound can thus serve as a point-of-care, cost-effective, easily available bedside tool for indirectly measuring intracranial pressures in this high-risk population.
包括颅内压升高在内的神经系统表现是子痫前期恶化的标志。尽管有创方法测量颅内压是金标准,但并非总是可行的选择。产妇眼部超声是一种很有前途的床边工具,可作为一种非侵入性、具有成本效益的方法来测量视神经鞘直径(ONSD),这是颅内压升高的替代标志物。我们研究了重度子痫前期妇女的超声测量 ONSD 值,以及硫酸镁治疗对其值的影响。
纳入了 30 名≥28 周妊娠的重度子痫前期妇女。我们记录了基线 ONSD 值、血清镁水平、神经系统症状、生命体征,并在硫酸镁治疗后 4 小时和 12 小时以及产后 24 小时重复测量,然后记录。ONSD 值>5.8mm 提示颅内压升高。主要观察指标是评估硫酸镁预防惊厥后超声测量的 ONSD 值的变化。
73.3%的妇女基线 ONSD>5.8mm,平均直径明显较高(6.02±0.77mm)。在 4 小时和 12 小时以及产后 24 小时,平均 ONSD 值呈统计学上无显著下降。在硫酸镁治疗后,有神经系统症状的患者显著减少(从 70%降至 10%;p 值<.001)。
大多数重度子痫前期产妇的 ONSD 值较高,提示颅内压升高,且在产后持续存在,硫酸镁治疗对此无影响。因此,超声可作为一种床边即时、具有成本效益、易于获取的工具,用于间接测量高危人群的颅内压。